Juergen Krauss

715 total citations
14 papers, 167 citations indexed

About

Juergen Krauss is a scholar working on Oncology, Molecular Biology and Otorhinolaryngology. According to data from OpenAlex, Juergen Krauss has authored 14 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Otorhinolaryngology. Recurrent topics in Juergen Krauss's work include Colorectal Cancer Treatments and Studies (5 papers), Head and Neck Cancer Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Juergen Krauss is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Head and Neck Cancer Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Juergen Krauss collaborates with scholars based in Germany, Spain and United States. Juergen Krauss's co-authors include Dirk Strumberg, Beate Schultheis, K. Mross, Jan Kuhlmann, Gunnar Folprecht, C.-H. Köhne, Oliver Boix, John Lettieri, Ulrich Hacker and R. Fischer and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Juergen Krauss

14 papers receiving 162 citations

Peers

Juergen Krauss

ONCOL

PRM

RNMI

HEPAT

Akesu Sujie China

Carole Massabeau France

Marie-Paule Sablin France

Yakup Ergün Türkiye

S. Korfee Germany

B.C. Cho South Korea

Arnaldo Marín Chile

Carlotta Defferrari Italy

Teruyoshi Ishida Japan

Shumei Jiang China

Akesu Sujie China

Juergen Krauss

114 ×1.0

ONCOL

35 ×0.7

90 ×1.9

PRM

14 ×0.5

RNMI

13 ×0.5

HEPAT

Citations per year, relative to Juergen Krauss Juergen Krauss (= 1×) peers Akesu Sujie

Countries citing papers authored by Juergen Krauss

Since Specialization

Citations

This map shows the geographic impact of Juergen Krauss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Krauss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Krauss more than expected).

Fields of papers citing papers by Juergen Krauss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen Krauss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Krauss. The network helps show where Juergen Krauss may publish in the future.

Co-authorship network of co-authors of Juergen Krauss

This figure shows the co-authorship network connecting the top 25 collaborators of Juergen Krauss. A scholar is included among the top collaborators of Juergen Krauss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juergen Krauss. Juergen Krauss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Eigentler, Thomas, Lucie Heinzerling, Juergen Krauss, et al.. (2021). 1010P Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008. Annals of Oncology. 32. S853–S853. 3 indexed citations

Adeberg, Sebastian, Paul Windisch, Felix Ehret, et al.. (2019). Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma. Frontiers in Oncology. 9. 1420–1420. 7 indexed citations

Hauswald, Henrik, Alexandra D Jensen, Juergen Krauss, et al.. (2018). Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clinical and Translational Radiation Oncology. 13. 64–73. 4 indexed citations

Siu, Lillian L., Caroline Even, Ricard Mesı́a, et al.. (2018). A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1307–1307. 7 indexed citations

Terheyden, Patrick, Carsten Weishaupt, Lucie Heinzerling, et al.. (2018). Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors. Annals of Oncology. 29. viii466–viii466. 4 indexed citations

Schultheis, Beate, Gunnar Folprecht, Jan Kuhlmann, et al.. (2013). Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals of Oncology. 24(6). 1560–1567. 78 indexed citations

Vermorken, Jan B., Frédéric Peyrade, Juergen Krauss, et al.. (2012). Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.. Journal of Clinical Oncology. 30(15_suppl). 5516–5516. 6 indexed citations

Schultheis, Beate, Gunnar Folprecht, Jan Kuhlmann, et al.. (2011). Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.. Journal of Clinical Oncology. 29(15_suppl). 3585–3585. 11 indexed citations

Schultheis, Beate, Gunnar Folprecht, Jan Kuhlmann, et al.. (2011). FOLFOX or FOLFIRI in combination with sequentially administered regorafenib as first- or second-line treatment in patients with colorectal cancer. 1 indexed citations

10.

Strumberg, Dirk, Beate Schultheis, M. E. Scheulen, et al.. (2010). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. International Journal of Clinical Pharmacology and Therapeutics. 48(7). 473–475. 12 indexed citations

11.

Krauss, Juergen, M. E. Scheulen, Dirk Strumberg, et al.. (2009). Pharmacokinetic study of S-1. International Journal of Clinical Pharmacology and Therapeutics. 47(1). 65–67. 2 indexed citations

12.

Strumberg, Dirk, M. E. Scheulen, Ralf A. Hilger, et al.. (2006). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). Journal of Clinical Oncology. 24(18_suppl). 12504–12504. 8 indexed citations

13.

Krauss, Juergen, Michaela A.E. Arndt, Zhongyu Zhu, et al.. (2004). Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. British Journal of Cancer. 90(9). 1863–1870. 21 indexed citations

14.

Krauss, Juergen, et al.. (1982). Platelet Dysfunction (Thrombocytopathy) in Extrahepatic Biliary Obstruction. Southern Medical Journal. 75(4). 506–506. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact